This Is MS Multiple Sclerosis Community: Knowledge & Support

Teva Pharmaceutical Industries Ltd. (TEVA) sued Synthon BV for infringing seven patents in planning to sell a generic version of the multiple sclerosis drug Copaxone before Teva’s patents expire.

Teva, based in Petach Tikva, Israel, said it licensed the patents from Yeda Research & Development Co., according to the lawsuit filed yesterday in federal court in New York.

Copaxone, used to reduce the frequency of relapses in multiple sclerosis patients, generated sales (TEVA) of $3.9 billion in 2011. Synthon filed an application with the U.S. Food and Drug Administration seeking approval of a generic version of the drug, according to the complaint.

“Defendants plan to begin manufacturing, marketing, selling, offering to sell and/or importing Synthon’s generic glatiramer acetate product soon after FDA approval,” Teva said in the complaint. “Such conduct will constitute direct infringement.”... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1903

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis

Is this the same lawsuit from last year? A trial began in September or October last year and then it just stopped for some unknown reason. It was a case about their patent.